Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Johannesburg Stock Exchange  >  Aspen Pharmacare Holdings Limited    APNJ   ZAE000066692

ASPEN PHARMACARE HOLDINGS LIMITED (APNJ)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Aspen Pharmacare : to buy remaining AstraZeneca anaesthetic rights for up to $766 million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 09:11am CEST
A man walks past a sign at an AstraZeneca site in Macclesfield

LONDON (Reuters) - AstraZeneca (>> AstraZeneca) said on Thursday it had agreed to sell the U.S. rights to a portfolio of anaesthetics to South Africa's Aspen Group (>> Aspen Pharmacare Holdings Limited) for up to $766 million (579.86 million pounds), a year after Aspen bought the rights outside the United States.

LONDON (Reuters) - AstraZeneca (>> AstraZeneca) said on Thursday it had agreed to sell the U.S. rights to a portfolio of anaesthetics to South Africa's Aspen Group (>> Aspen Pharmacare Holdings Limited) for up to $766 million (579.86 million pounds), a year after Aspen bought the rights outside the United States.

The British group said it would continue to manufacture and supply the seven medicines - Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest - for a transition period of up to five years.

"Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas," said AstraZeneca executive Mark Mallon.

AstraZeneca is focusing on oncology, cardiovascular and metabolic diseases and respiratory treatments.

It said the deal, which comprises an upfront $555 million and performance related payments of up to $211 million, did not change its financial guidance for 2017.

(Reporting by Paul Sandle; editing by Jason Neely)

Stocks treated in this article : Aspen Pharmacare Holdings Limited, AstraZeneca
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -0.49% 5229 Delayed Quote.2.11%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASPEN PHARMACARE HOLDINGS
05/11JSE LIMITED : - Aspen opens R1 billion high containment facility
AQ
05/04SOUTH AFRICA : Minister Davies to Open R1 Billion Aspen's High Containment Facil..
AQ
05/04SOUTH AFRICA : Minister Davies to Open R1 Billion Aspen’s High Containment..
AQ
03/09ASPEN PHARMACARE : resolves tax dispute with Sars
AQ
03/05ASPEN PHARMACARE HOLDINGS LIMITED : half-yearly earnings release
01/30ASPEN PHARMACARE : seeks new formula
AQ
01/17ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
RE
01/16ASPEN PHARMACARE : wants trades audited
AQ
01/11ASPEN PHARMACARE : share price knocked by rumours of investigation target
AQ
01/11ASPEN PHARMACARE : claims manipulation
AQ
More news
News from SeekingAlpha
03/09Aspen Pharmacare Holdings Plc ADR 2018 Q2 - Results - Earnings Call Slides 
2017Aspen Pharmacare Holdings (APNHY) Investor Presentation - Slideshow 
2017Aspen Pharmacare Has Continued To Grow And Branch Out 
2016Wobbles Aside, Small Pharma Shares Broadly On The Up In 2015 
2015Sector's Smaller Players Show The Way 
Financials ( ZAR)
Sales 2018 44 324 M
EBIT 2018 11 365 M
Net income 2018 5 467 M
Debt 2018 42 492 M
Yield 2018 1,31%
P/E ratio 2018 15,54
P/E ratio 2019 14,24
EV / Sales 2018 3,63x
EV / Sales 2019 3,41x
Capitalization 118 B
Chart ASPEN PHARMACARE HOLDINGS
Duration : Period :
Aspen Pharmacare Holdings  Technical Analysis Chart | APNJ | ZAE000066692 | 4-Traders
Technical analysis trends ASPEN PHARMACARE HOLDINGS
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 304  ZAR
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Stephen Bradley Saad Group Chief Executive Officer & Executive Director
Douglas Dlamini Chairman
Lorraine Hill Group Operating Officer
Sean Capazorio Group Finance Officer
Michael Guy Attridge Executive Director & Group Deputy CEO